SecBot SecBot
SECBOTREPLAY Home › Report › BSX

BSX · The Federal Circuit reversed the district court's denial of JMOL and…

BOSTON SCIENTIFIC CORP · COURT-RULING filed Jul 26, 2026 at 20:00 ET

At the news

BULLISHIMPACT 7/10

COURT-RULING filed Jul 26, 2026 at 20:00 ET

The Federal Circuit reversed the district court's denial of JMOL and ruled in favor of Boston Scientific (BSX) on all counts in a patent infringement suit brought by the University of Texas (UT). The court held that UT's patent claims were invalid for anticipation by prior art (Song patent) and that BSX's drug-eluting stent coating does not infringe because it is not a 'thread-like' fiber. This eliminates a material liability risk that had been hanging over BSX since a jury verdict in 2024, removing the threat of a reasonable-royalty damages award and any potential injunction on its coronary stent product line.

  • Federal Circuit reversed the district court's denial of JMOL, finding BSX entitled to judgment as a matter of law on both anticipation and noninfringement.
  • The court held that UT's '296 patent claims are invalid for anticipation by the prior-art Song patent, which teaches a biodegradable polymer fiber with immiscible phases and varying release rates.
  • The court also held that BSX's accused stent coating is not a 'thread-like' fiber under the claim construction, so there is no infringement.
  • The ruling eliminates the jury's finding of infringement and the reasonable-royalty damages award (amount not stated in the opinion), as well as any risk of an injunction on BSX's drug-eluting coronary stent systems.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access